Replies to post #92 on Aida Pharmaceuticals (AIDA)

[QFA2008]

Q1 is Aida's weakest quarter, but we do see revenues increase 44.48%, gross profit increase 70% from Q107 to Q108.
No write off for $7m. I was waiting for that and put buy order at 0.52; try to load up more shares for that.
Well, not that lucky.
Now all bad news are gone and two good news are coming soon: Rh-Apo2L phase II result and phase III test approval by SFDA.

[BMiles]

As we have discussed, the $7 million will take a while to play out, I don't know how quickly China moves on this type of stuff in comparison to the US. I will agree with you that I may have been a little heavy on the optimistic side of seeing a full return of the $7 million but I guess for once my optimism seems as if it will pay off. The 10Q only spoke about the valuation of the building and recovering the $7 million from just that asset, keep in mind their were other assets siezed as well so I feel pretty good about fully recovering the $7 million.

Now perhaps this stock can get back up to the $1.20 trading range or higher quickly. News by the 28th about Rh-Apo2L should help, my guess is they probably could not put any information out on that until they filed their 10Q.

Brad